Resistance to minor groove binders

Benedetta Colmegna, Sarah Uboldi, Eugenio Erba, Maurizio D'Incalci

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In this paper multiple resistance mechanisms to minor groove binders (MGBs) are overviewed. MGBs with antitumor properties are natural products or their derivatives and, as expected, they are all substrates of P-glycoprotein (P-gp). However, a moderate expression of P-gp does not appear to reduce the sensitivity to trabectedin, the only MGB so far approved for clinical use. Resistance to this drug is often related to transcriptional mechanisms and to DNA repair pathways, particularly defects in transcription-coupled nucleotide excision repair (TC-NER). Therefore tumors resistant to trabectedin may become hypersensitive to UV rays and other DNA damaging agents acting in the major groove, such as Platinum (Pt) complexes. If this is confirmed in clinic, that will provide the rationale to combine trabectedin sequentially with Pt derivates.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalDrug Discovery Today: Technologies
Volume11
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

trabectedin
P-Glycoprotein
Platinum
DNA Repair
Biological Products
Drug Resistance
DNA
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Biotechnology
  • Molecular Medicine
  • Medicine(all)

Cite this

Resistance to minor groove binders. / Colmegna, Benedetta; Uboldi, Sarah; Erba, Eugenio; D'Incalci, Maurizio.

In: Drug Discovery Today: Technologies, Vol. 11, No. 1, 2014, p. 73-79.

Research output: Contribution to journalArticle

Colmegna, Benedetta ; Uboldi, Sarah ; Erba, Eugenio ; D'Incalci, Maurizio. / Resistance to minor groove binders. In: Drug Discovery Today: Technologies. 2014 ; Vol. 11, No. 1. pp. 73-79.
@article{a4374eec884a4288b45a37d00ceb9d9a,
title = "Resistance to minor groove binders",
abstract = "In this paper multiple resistance mechanisms to minor groove binders (MGBs) are overviewed. MGBs with antitumor properties are natural products or their derivatives and, as expected, they are all substrates of P-glycoprotein (P-gp). However, a moderate expression of P-gp does not appear to reduce the sensitivity to trabectedin, the only MGB so far approved for clinical use. Resistance to this drug is often related to transcriptional mechanisms and to DNA repair pathways, particularly defects in transcription-coupled nucleotide excision repair (TC-NER). Therefore tumors resistant to trabectedin may become hypersensitive to UV rays and other DNA damaging agents acting in the major groove, such as Platinum (Pt) complexes. If this is confirmed in clinic, that will provide the rationale to combine trabectedin sequentially with Pt derivates.",
author = "Benedetta Colmegna and Sarah Uboldi and Eugenio Erba and Maurizio D'Incalci",
year = "2014",
doi = "10.1016/j.ddtec.2014.03.001",
language = "English",
volume = "11",
pages = "73--79",
journal = "Drug Discovery Today: Technologies",
issn = "1740-6749",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Resistance to minor groove binders

AU - Colmegna, Benedetta

AU - Uboldi, Sarah

AU - Erba, Eugenio

AU - D'Incalci, Maurizio

PY - 2014

Y1 - 2014

N2 - In this paper multiple resistance mechanisms to minor groove binders (MGBs) are overviewed. MGBs with antitumor properties are natural products or their derivatives and, as expected, they are all substrates of P-glycoprotein (P-gp). However, a moderate expression of P-gp does not appear to reduce the sensitivity to trabectedin, the only MGB so far approved for clinical use. Resistance to this drug is often related to transcriptional mechanisms and to DNA repair pathways, particularly defects in transcription-coupled nucleotide excision repair (TC-NER). Therefore tumors resistant to trabectedin may become hypersensitive to UV rays and other DNA damaging agents acting in the major groove, such as Platinum (Pt) complexes. If this is confirmed in clinic, that will provide the rationale to combine trabectedin sequentially with Pt derivates.

AB - In this paper multiple resistance mechanisms to minor groove binders (MGBs) are overviewed. MGBs with antitumor properties are natural products or their derivatives and, as expected, they are all substrates of P-glycoprotein (P-gp). However, a moderate expression of P-gp does not appear to reduce the sensitivity to trabectedin, the only MGB so far approved for clinical use. Resistance to this drug is often related to transcriptional mechanisms and to DNA repair pathways, particularly defects in transcription-coupled nucleotide excision repair (TC-NER). Therefore tumors resistant to trabectedin may become hypersensitive to UV rays and other DNA damaging agents acting in the major groove, such as Platinum (Pt) complexes. If this is confirmed in clinic, that will provide the rationale to combine trabectedin sequentially with Pt derivates.

UR - http://www.scopus.com/inward/record.url?scp=84899965209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899965209&partnerID=8YFLogxK

U2 - 10.1016/j.ddtec.2014.03.001

DO - 10.1016/j.ddtec.2014.03.001

M3 - Article

VL - 11

SP - 73

EP - 79

JO - Drug Discovery Today: Technologies

JF - Drug Discovery Today: Technologies

SN - 1740-6749

IS - 1

ER -